Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gardasil 9 + QDENGA
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Gardasil 9 + QDENGA refers to the co-administration of two distinct vaccines: Takeda's tetravalent dengue vaccine (TAK-003, brand name QDENGA) and Merck's 9-valent human papillomavirus (HPV) vaccine (Gardasil 9). TAK-003 is a live-attenuated vaccine based on a dengue virus serotype 2 (DENV-2) backbone, with chimeric strains expressing surface antigens for DENV-1, DENV-3, and DENV-4, providing protection against all four dengue serotypes. Gardasil 9 is a recombinant vaccine composed of virus-like particles (VLPs) targeting nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). A Phase 3 clinical trial (NCT04313244) conducted in Thailand evaluated the safety and immunogenicity of co-administering these vaccines in healthy adolescents aged 9 to 14 years. The study demonstrated that the immune response to both vaccines was non-inferior when administered together compared to separate administration, with a safety profile consistent with the individual vaccines.
- Brand names
- Gardasil 9Gardasil9Gardasil-9QDENGA
- Other names
- 9vHPV vaccine-Takeda-dengue feverTDV9vHPV9-valent human papillomavirus vaccineDengue Tetravalent Vaccine
02
Targets
prM/E (Dengue virus premembrane and envelope proteins)Dengue virus nonstructural proteinsHPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on Gardasil 9 + QDENGA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gardasil 9 + QDENGA.